Anti-Endotoxin Monoclonal Antibodies — A Second Look
- 23 April 1992
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 326 (17) , 1151-1153
- https://doi.org/10.1056/nejm199204233261710
Abstract
Approximately half a million cases of sepsis occur each year in the United States, and the estimated mortality is 35 percent (175,000 deaths annually). Half are caused by gram-negative rods, and half of these are associated with a positive blood culture. Among patients with positive blood cultures, 25 percent die of complications directly attributable to the bacteremia and 10 percent die of the underlying disease.1 Improved therapies directed at the infection would not affect the latter.Bloodstream infections also add to the morbidity and economic burden of the underlying diseases. The excess hospital stay attributable to nosocomial bacteremia (two weeks) . . .Keywords
This publication has 9 references indexed in Scilit:
- Anti-Endotoxin Monoclonal AntibodiesNew England Journal of Medicine, 1992
- Antiendotoxin Monoclonal Antibodies for Gram-Negative Sepsis: Guidelines from the IDSAClinical Infectious Diseases, 1992
- Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agentJAMA, 1991
- A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study GroupPublished by American Medical Association (AMA) ,1991
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- Sepsis syndromeCritical Care Medicine, 1989
- The Mortality of Hospital-Acquired Bloodstream Infections: Need for a New Vital Statistic?International Journal of Epidemiology, 1988
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982
- Gram-negative bacteremiaThe American Journal of Medicine, 1980